FDA Breakthrough Dev...
19th July 2022 Content supplied by: bioMérieux (Clinical Diagnostics)
Added Medical Value with Urine Sample Results Up to 8 Hours Faster
Culture media may not seem like a big deal in the age of sophisticated automation in the microbiology lab, but in fact, it has a big impact on quality and reliability of results for better patient management.
Direct culture media reading and faster delivery of patient results contribute to rapid diagnosis of urinary tract infections (UTI). What if your lab could accelerate ID/AST tests and report actionable results to clinicians as much as a full day earlier?
Always committed to offering labs what they need to enable added medical value, bioMérieux now goes one step further to optimize urine workflow. When used with WASPLab® with PhenoMatrix™, CHROMID® CPS Elite media Early Reading facilitates URINE FLOW in just 10-12h. This adds up to new perspectives for urine sample management. With this unique addition, microbiology labs can gain up to 8 hours in comparison to the current routine urine workflow, while ensuring a high recovery rate of E. coli (representing 70% of the UTI epidemiology).
CHROMID® CPS Elite media - 12h reading time (mixed culture of E.coli + KESC)
With 59 years of experience in microbiology, bioMérieux is your best-equipped partner in microbiology solutions to help your clinicians make faster decisions with confidence.
What is the performance of CHROMID® URINE FLOW at early reading? Watch this customer experience video featuring Dr. Arnaud Francois, Clinical Microbiologist, Bioesterel Biogroup Laboratory, France.
Tags:
Date Published: 19th July 2022
Source article link: View
FDA Breakthrough Device Designation for
bioMérieux (Clinical Diagnostics)
Address:
Marcy L'Etoile
France
Related news from bioMérieux (Clinical Diagnostics)
- BIOFIRE® SPOTFIRE® Respiratory/Sore Throat Panel Mini Receives FDA Special Clearance and CLIA Waiver
- bioMérieux's AST System VITEK® REVEAL Achieves FDA 510(k) Clearance
- FDA Clearance and CLIA-waiver for bioMerieux's BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel
- US FDA CLIA-waiver for BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
- BioFire Defense Partners With BARDA
- FDA Clearance and CLIA-waiver for Fast and Innovative BIOFIRE® SPOTFIRE® POC System
- MAESTRIA™, a New Generation Microbiology Middleware Optimizes Laboratory Workflow
- VIDAS® KUBE™ - the Next-generation VIDAS® System Receives CE Marking
- FDA Breakthrough Device Designation for SPECIFIC REVEAL® Rapid AST System
- bioMérieux to Distribute Specific Diagnostics’ REVEAL Rapid AST System in Europe
- Enhanced BIOFIRE® Blood Culture Identification 2 (BCID2) Panel Submitted for FDA Clearance
- Spotlight on Antimicrobial Stewardship with bioMérieux
- New FDA Clearance for VITEK® MS: Expanded ID for Challenging Pathogens
- PhenoMATRIX™ for WASPLab®: AI for Sample Interpretation & Sorting
- BIOFIRE® FILMARRAY® Pneumonia Panels Gain FDA clearance and CE Marking
- bioMérieux and DIAGNOSTICS IS POWER at ECCMID 2018
- FDA Clears Identification of Mycobacteria, Nocardia and Moulds on VITEK® MS
- FDA Clearance for BacT/ALERT® VIRTUO™ Fully Automated Blood Culture System
- bioMérieux Your Expert in Infectious Diseases at ECCMID 2017
- bioMérieux Awarded Multi-year Agreement with NHS for Bacterial Screening of Platelets